Skip to main navigation

Investor Relations

October 18, 2021

ABX464 shows excellent long-term efficacy data in Abivax’s phase 2b maintenance trial in ulcerative colitis

September 30, 2021

Abivax announces the release of its half-year financial report 2021

September 28, 2021

Abivax late-breaking abstract presentation and Live Industry Symposium at UEG Week Virtual 2021

September 23, 2021

Abivax presents first-half 2021 financial results and operations update

September 14, 2021

Abivax provides an update on the ABX464 clinical data and development strategy in ulcerative colitis